Apremilast for Behçet's syndrome - A phase 2, placebo-controlled study

New England Journal of Medicine

Volumn 372, Issue 16, 2015, Pages 1510-1518

  Hatemi, Gulen ^a   Melikoglu, Melike ^a   Tunc, Recep ^b   Korkmaz, Cengiz ^c   Ozturk, Banu Turgut ^b   Mat, Cem ^a   Merkel, Peter A ^d   Calamia, Kenneth T ^e   Liu, Ziqi ^f   Pineda, Lilia ^f   Stevens, Randall M ^f   Yazici, Yusuf ^g   Yazici, Hasan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b SELCUK UNIVERSITY   (Turkey)

^c ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MAYO CLINIC   (United States)

^f CELGENE CORPORATION   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; PLACEBO; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; ANUS FISSURE; ARM PAIN; ARTHRALGIA; ARTICLE; ASTHENIA; BEHCET DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GENITAL ULCER; HEADACHE; HEMORRHOID; HUMAN; INFLUENZA; LEG PAIN; MAJOR CLINICAL STUDY; MALE; METRORRHAGIA; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; PARALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNIVERSITY HOSPITAL; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; VOMITING; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BEHCET SYNDROME; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; ORAL ULCER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BEHCET SYNDROME; DOUBLE-BLIND METHOD; FEMALE; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; MALE; ORAL ULCER; PHOSPHODIESTERASE 4 INHIBITORS; THALIDOMIDE;

EID: 84928019857     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1408684     Document Type: Article

References (18)

1. Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidencebased recommendations for the management of Behçet disease. Ann Rheum Dis 2009; 68: 1528-34.
2. Aktulga E, Altaç M, Müftüoglu A, et al. A double blind study of colchicine in Behçet's disease. Haematologica 1980; 65: 399-402.
3. Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001; 44: 2686-92.
4. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19: 542-9.
5. Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med 2013; 11: 96.
6. Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb) 2013; 3: 1-15.
7. Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel- group, dose-comparison study. J Eur Acad Dermatol Venereol 2013; 27(3): e376-e383.
8. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380: 738-46.
9. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64: 3156-67.
10. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
11. Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9.
12. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
13. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728-33.
14. Forbess C, Swearingen C, Yazici Y. Behçet's Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-driven measures only, is strongly correlated with the Behçet's Disease Current Activity Form (BDCAF). Presented at the 72nd Annual Scientific Meeting of the American College of Rheumatology, San Francisco, October 24-29, 2008. abstract (https:/ / acr .confex .com/ acr/ 2008/ webprogram/ Paper2192 .html).
15. Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the BD-QoL: a quality of life measure specific to Behçet's disease. J Rheumatol 2004; 31: 931-7.
16. Ware JE Jr. SF-36 Health Survey update (http://www .sf-36 .org/ tools/ SF36 .shtml).
17. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32: 98-105.
18. Yurdakul S, Yazici Y. Epidemiology of Behçet's syndrome and regional differences in disease expression. In: Yazici H, Yazici Y, eds. Behçet's syndrome. New York: Springer Science and Business Media, 2010: 35-52.